Amgen shared new findings about Repatha that show it helps lower cholesterol for high-risk patients.

AMGN · Amgen

The AI's read

Doctors now have support for considering Repatha in more high-risk patients. The report also calls it cost-effective, which could make its use easier to justify. Still, the story gives no sales or prescription figures, so any business gain has not been shown.